How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,469 results for

First Generation Sulfonylurea

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada : Diabetes in the elderly

, side effects and adverse drug interactions . Drugs that can be considered first for deprescribing in these individuals include statins and sulfonylureas, because of lack of benefit in people with limited life expectancy and concerns about hypoglycemia, respectively. Diabetes in Long-Term Care The prevalence of diabetes is high in institutions and individuals frequently have established microvascular and CV complications, as well as substantial comorbidity . Canadian data shows over 25% of residents (...) because the risk of hypoglycemia increases substantially with age [Grade D, Level 4 ]. DPP-4 inhibitors should be used over sulfonylureas as second-line therapy to metformin because of a lower risk of hypoglycemia [Grade B, Level 2 ] In general, initial doses of sulphonylureas in the older person should be half of those used for younger people, and doses should be increased more slowly [Grade D, Consensus] Gliclazide and gliclazide MR [Grade B, Level 2 ] and glimepiride [Grade C, Level 3 ] should

2013 CPG Infobase

122. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

Recommendations Recommendations 1.1 Canagliflozin, dapagliflozin and empagliflozin as monotherapies are recommended as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if: a dipeptidyl peptidase-4 (DPP-4) inhibitor would otherwise be prescribed and a sulfonylurea or pioglitazone is not appropriate. 1.2 Adults whose treatment with canagliflozin, dapagliflozin or empagliflozin (...) that given the infrequency of reported hypoglycaemia, the similar outcomes between active and placebo arms, and the cut-off level used, it was reasonable to assume that the SGLT-2 inhibitors did not cause hypoglycaemia. For cholesterol, not all trials reported all outcomes. Generally, the SGLT-2 inhibitors led to increases in all types of cholesterol. Adverse effects of treatment 3.9 The AG reviewed outcomes related to adverse effects of treatment in the clinical trials. The SGLT-2 inhibitors were

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

123. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence

further research. Throughout, we emphasize that this document is not a comprehensive review of the literature but rather a focus on the major new trials that have led to recent guideline changes in the area of primary prevention of CVD in type 2 diabetes mellitus. New Diagnostic Criteria for Diabetes Mellitus and Prediabetes In 2010, the ADA included A 1c for the first time among the tests recommended for the diagnosis of diabetes mellitus. This recommendation has also been adopted by the European (...) , legumes, vegetables, whole grains, and dairy products in place of other carbohydrate sources ( ADA Level of Evidence B ).Mediterranean-style dietary pattern may improve glycemic control and CVD risk factors ( ADA Level of Evidence B ).Limit of sodium to <2300 mg/d, similar to recommendations for the general population ( ADA Level of Evidence B ; note that the AHA differs and recommends sodium <1500 mg/d). Obesity “2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults

Full Text available with Trip Pro

2015 American Heart Association

124. Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus

in CVD Risk Factors and Outcomes in DM Sex Differences Risk factor Sex hormones: testosterone High bioavailable or unbound testosterone predicts incident coronary events Low levels of total testosterone predict incident coronary events Generalized obesity Higher prevalence of obesity in women, particularly postmenopausal women, than men HDL-C Women have higher HDL-C compared with men Hypertension Women with DM have more hypertension at >60 y of age (ie, postmenopausal) Men with DM and hypertension (...) in DM? For years, it has been recognized that the incidence of coronary heart disease (CHD) in women lags behind that of men by ≈10 years, thus generating hypotheses that differences in endogenous sex steroid levels contribute to sex differences in CHD. It also has been recognized for years that DM confers greater risk for CHD death in women compared with men. Early Rancho Bernardo Study publications noted that men with DM by history or by fasting plasma glucose had a 2.4-fold excess risk

Full Text available with Trip Pro

2015 American Heart Association

125. Second and Third-line Therapies for Type 2 Diabetes

nutrition, and adequate exercise), medications, such as metformin and sulfonylureas, play an important role in achieving glycemic control in patients with diabetes mellitus: Metformin is a popular first-line oral antidiabetes drug that is used to help control glycemic levels in patients with diabetes when lifestyle modifications alone are insufficient. Because diabetes is a progressive disease, metformin monotherapy may eventually fail to adequately control glycemic levels. At this point, most patients (...) need one or more oral antidiabetes drug, or insulin, added as a second-line therapy to their treatment regimen. If, after time, second-line therapy fails, most patients will need one or more additional drugs added as a third-line therapy to achieve target glycemic levels. In Canada, seven classes of antidiabetes drugs are available that may be used as second- and third-line therapy: sulfonylureas, meglitinides, alpha-glucosidase inhibitors, thiazolidinediones, incretin agents, weight loss agents

2015 CADTH - Optimal Use

126. Second- and Third-line Therapies for Type 2 Diabetes

nutrition, and adequate exercise), medications, such as metformin and sulfonylureas, play an important role in achieving glycemic control in patients with diabetes mellitus: Metformin is a popular first-line oral antidiabetes drug that is used to help control glycemic levels in patients with diabetes when lifestyle modifications alone are insufficient. Because diabetes is a progressive disease, metformin monotherapy may eventually fail to adequately control glycemic levels. At this point, most patients (...) need one or more oral antidiabetes drug, or insulin, added as a second-line therapy to their treatment regimen. If, after time, second-line therapy fails, most patients will need one or more additional drugs added as a third-line therapy to achieve target glycemic levels. In Canada, seven classes of antidiabetes drugs are available that may be used as second- and third-line therapy: sulfonylureas, meglitinides, alpha-glucosidase inhibitors, thiazolidinediones, incretin agents, weight loss agents

2015 CADTH - Optimal Use

127. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min)

dialysis or haemodialysis as a first modality? Statements 1.1.1 We recommend giving priority to the patient's general status and preference in selecting renal replacement therapy as there is an absence of evidence of superiority of one modality over another in patients with diabetes and CKD stage 5 (1C). 1.1.2 We recommend providing patients with unbiased information about the different available treatment options (1A). 1.1.3 In patients opting to start haemodialysis (HD), we suggest prefering high (...) is this guideline for? This guideline intends to support clinical decision making by any health care professional caring for patients with diabetes and CKD stage 3b or higher (eGFR <45 mL/min), i.e. for general practitioners, internists, surgeons and other physicians dealing with this specific patient population in both an outpatient and an in-hospital setting. The guideline also aims to inform about the development of standards of care by policy-makers. 5.3. What is this guideline about? The intended scope

Full Text available with Trip Pro

2015 European Renal Best Practice

128. Empagliflozin (Jardiance) - type 2 diabetes mellitus

measures is a prerequisite to drug treatment for glycaemic control. Drug strategy: According to the HAS guidelines, if the glycaemic target is not met despite the implementation of lifestyle and dietary measures, monotherapy should be started with metformin as the first-line treatment or, if there are contraindications, with sulfonylureas. If both these drugs are contraindicated, the alternatives are: - repaglinide in patients who eat at irregular intervals, since it is administered with every meal (...) (short half-life); - alpha-glucosidase inhibitors if episodes of hypoglycaemia give cause for concern. If there are symptoms or very poorly controlled diabetes with recurrent blood glucose levels above 3 g/l or with an HbA1c greater than 10%, dual therapy or insulin therapy may be initiated from the start. Combinations recommended as dual therapy: If the glycaemic target is not achieved with monotherapy, dual therapy is recommended, combining metformin and sulfonylureas as first-line treatment

2015 Haute Autorite de sante

129. Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes

remove one or more studies before adding more. Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00974090 Recruitment Status : Completed First Posted : September 10, 2009 Results First Posted : May 8 (...) Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2009 Clinical Trials

130. CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

studies (100). Please remove one or more studies before adding more. CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00968812 Recruitment Status : Completed First Posted : August 31, 2009 (...) CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2009 Clinical Trials

131. Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

number of saved studies (100). Please remove one or more studies before adding more. Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00995787 Recruitment Status : Completed First (...) Principal Investigator: Marcus Dr. Marcus Hompesch, Dr Profil Institute for Clinical Research Inc.855 3rd Avenue, Suite 4400Chula VistaCA 91911, USA More Information Go to Layout table for additonal information Responsible Party: MSD, AstraZeneca ClinicalTrials.gov Identifier: Other Study ID Numbers: D1020C00026 First Posted: October 15, 2009 Last Update Posted: February 26, 2010 Last Verified: February 2010 Keywords provided by AstraZeneca: Type II diabetes mellitus metformin sulfonylurea Additional

2009 Clinical Trials

132. GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)

Party: Sanofi ClinicalTrials.gov Identifier: Other Study ID Numbers: EFC10887 First Posted: March 20, 2009 Results First Posted: October 11, 2016 Last Update Posted: October 11, 2016 Last Verified: August 2016 Keywords provided by Sanofi: hyperglycemia GLP-1 sulfonylurea insulin Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Insulin Insulin, Globin Zinc Lixisenatide (...) GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search

2009 Clinical Trials

133. Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information (...) . Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does

2009 Clinical Trials

134. Cardiovascular Disease Risk Factors in Youth With Diabetes Mellitus

pediatric T2DM should be associated with weight loss or at least should have a weight-neutral effect. According to recent guidelines from the American Academy of Pediatrics, metformin should be the first-line therapy for the treatment of pediatric T2DM. In general, metformin is associated with modest weight loss. Three randomized, placebo-controlled trials conducted in obese youth without diabetes mellitus reported a BMI reduction of ≈3% over a treatment period of 6 to 12 months. Neither glucagon-like (...) and require further study. In the general population, female individuals have lower CVD risk than male individuals. However, this protective effect of female sex is lost with T1DM; CVD risk in female individuals approaches that of male individuals. , CVD risk factor management in T1DM needs to be improved. Type 2 Diabetes Mellitus Before the 1990s, T2DM was rarely diagnosed in youth, but increased rates now parallel the increasing rates of pediatric obesity. Although rates of T2DM in youth have increased

2014 American Heart Association

135. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing

contains three classes (I, II, and III). Major histocompatibility complex class I contains three genes: HLA-B, HLA-A, and HLA-C. HLA-B encodes a cell surface protein that binds peptides generated by proteolysis and extruded from proteasomes. The presentation of these peptides on the cell surface enables the immune system to distinguish self-proteins from foreign proteins typically intro- duced by infectious organisms (e.g., viruses and bacteria) (see Supplementary Material online for further discussion (...) by the gene name, which is followed by an asterisk and up to an eight-digit (four pairs) identifier giving information about the allele type (designated by the first two digits) and specific protein subtypes (second set of digits). For more information and a diagram outlining the description of the current HLA allele nomenclature, see http://hla.alleles.org/ Received 10 June 2014; accepted 31 July 2014; advance online publication 17 September 2014. doi:10.1038/clpt.2014.159 Clinical Pharmacology

2014 Clinical Pharmacogenetics Implementation Consortium

136. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics

Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics 1 © American College of Medical Genetics and Genomics ACMG St And ArdS And GuidelineS PURPOSE This guideline is intended as an educational resource. It high- lights current practices and therapeutic approaches to the diagnosis and management of GSD I and its early and long- term complications. GENERAL BACKGROUND History In 1929, von Gierke described glycogen (...) and discovered that the absence of the enzyme glucose-6-phos- phatase (G6Pase) caused von Gierke disease, establishing the first metabolic disorder in which an enzyme defect was identi- fied. Two patients had almost total deficiency of hepatic G6Pase; the remaining four patients had normal enzyme activity. Early on, the authors recognized the variability of the hepatic GSDs. In 1978, Narisawa et al. 3 explained the paradox of the four patients with GSD and normal enzyme activity when he described GSD type Ib

2014 American College of Medical Genetics and Genomics

137. Tenelia (teneligliptin hydrobromide hydrate)

Tenelia (teneligliptin hydrobromide hydrate) Report on the Deliberation Results April 27, 2012 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare [Brand name] Tenelia Tablets 20 mg [Non-proprietary name] Teneligliptin Hydrobromide Hydrate (JAN*) [Applicant] Mitsubishi Tanabe Pharma Corporation [Date of application] August 26, 2011 [Results of deliberation] In the meeting held on April 27, 2012, the First Committee on New Drugs (...) ] Type 2 diabetes mellitus; The drug product should be used only in patients who have not sufficiently responded to either of the following treatments. (a) Diet and/or exercise therapy alone (b) Use of sulfonylureas in addition to diet and/or exercise therapy (c) Use of thiazolidinediones in addition to diet and/or exercise therapy [Dosage and administration] The usual adult dosage is 20 mg of teneligliptin administered orally once daily. If efficacy is insufficient, the dose may be increased up

2012 Pharmaceuticals and Medical Devices Agency, Japan

138. Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03460769 Recruitment Status : Recruiting First Posted : March 9, 2018 Last Update Posted : October 5, 2018 See Sponsor: M.D. Anderson Cancer Center Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Information provided by (Responsible Party): M.D. Anderson Cancer Center Study Details Study Description Go (...) Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 40 Years to 84 Years (Adult, Older Adult) Sexes Eligible for Study: All

2018 Clinical Trials

139. A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use

Identifier: NCT03420040 Recruitment Status : Enrolling by invitation First Posted : February 2, 2018 Last Update Posted : February 2, 2018 Sponsor: Xijing Hospital Information provided by (Responsible Party): Xijing Hospital Study Details Study Description Go to Brief Summary: A clinical study of the use of glargine insulin in 2 subjects with type two diabetes in China was carried out. The two kinds of injection methods were evaluated as subcutaneous injection of insulin glargine. Condition or disease (...) glucose between baseline to week 4 [ Time Frame: baseline and week 4 ] fasting blood glucose are measured at baseline and week 4 Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information

2018 Clinical Trials

140. Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes

and Interventions Go to Arm Intervention/treatment Experimental: CinnaGen-liraglutide CinnaGen-liraglutide (Liraglutide 6 MG/ML Pen Injector by CinnaGen Company) will be administered 1.8 mg/day subcutaneously. Doses of CinnaGen-liraglutide will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non (...) Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study. Other Name: Sulfonylurea or non-sulfonylurea insulin secretagogues Active Comparator: Victoza® Victoza® (Liraglutide 6 MG/ML Pen Injector by Novo Nordisk Company) will be administered 1.8 mg/day subcutaneously. Doses of Victoza® will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>